Go to Top

PRESS RELEASES

2016: a historic year for VEXIM

2016: a historic year for VEXIM
Positive net income and net cash generation in the second half of 2016
Strong growth in SpineJack® sales in 2016: +33%, at €18.5 million
Strong gross margin: 72,2% of sales (vs. 71,5% in 2015)
Strong cash position: €9.8 million as of December 31st, 2016
(+ €0.3 million vs. June 30th, 2016)
2017 objectives: Perspectives of profitable growth
✓ Sales growth of +30% to +35% (organic)
✓ Positive net income and operating income …Lire plus

VEXIM: another major step towards the SpineJack® commercialization in the US

VEXIM: another major step towards the SpineJack® commercialization in the US

Completion of patient enrollment in the international clinical trial to support 510(k) submission for the SpineJack® in the US.

FDA 510(k) filing is planned by year-end leading to potential US launch in the first half of 2018, a market worth €500 million per year.

This trial evaluates safety & effectiveness of the SpineJack® in comparison with balloon kyphoplasty in 152 patients with …Lire plus

VEXIM strengthens its intellectual property protection for the SpineJack® in Asia

VEXIM strengthens its intellectual property protection for the SpineJack® in Asia: two patents granted in China and Japan
VEXIM is about to initiate the process of registration of its products in China
Toulouse (France), February 2nd, 2017 (8:30AM CET) –VEXIM (FR0011072602 – ALVXM / PEA‐PME eligible), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announces the expansion of its SpineJack® patent portfolio in Asia.
The issuance of …Lire plus

Vexim: Amendment of the financial agenda for 2017

Vexim: Amendment of the financial agenda for 2017
 
Toulouse (France), January 30th, 2017 (8:30AM CET) –VEXIM (FR0011072602 – ALVXM / PEA‐PME eligible), a medical device company specializing in the minimally invasive treatment of vertebral fractures, will announce its 2016 Full-Year Results on Wednesday, 22 March, 2017 – before the market opening.
The other dates announced on the original schedule remain unchanged:

Financial reporting schedule:
2016 Full-Year Results: March 22nd, 2017*
*indicative date, subject to change

VEXIM Strengthens its Management Team, through the appointment of Russell Powers as Vice President and General Manager for its US business

VEXIM Strengthens its Management Team,
through the appointment of Russell Powers
as Vice President and General Manager for its US business
 
Toulouse (France), January 19th, 2017 –VEXIM (FR0011072602 – ALVXM / PEA‐PME eligible), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announces the appointment of Russell Powers as Vice President and General Manager of its US business, effective January 1st, 2017.
Russell brings more than 25 years of …Lire plus

VEXIM sets new sales record in the 4th quarter 2016 and solidifies its position as a major player in spine trauma

VEXIM sets new sales record in the 4th quarter 2016 and solidifies its position as a major player in spine trauma

More than 6,900 patients treated with SpineJack® in 2016 and 20,000 since launch
€5.2 million in sales (up 24%) in the 4th quarter 2016
€18.5 million in sales (up 33%) in 2016 (+ €4.6 million vs. 2015)

 
Toulouse (France), January 17th, 2017 – VEXIM (FR0011072602 – ALVXM / PEA‐PME eligible), a medical device …Lire plus

VEXIM: Publication of the Shareholders’ Newsletter – December 2016

VEXIM: Publication of the Shareholders’ Newsletter – December 2016
 
Toulouse, December 15th, 2016 –VEXIM (FR0011072602 – ALVXM / PEA‐PME eligible), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announces the publication of its Shareholders’ Newsletter.
 Contents of this issue:
– Editorial of Vincent Gardès, CEO
– 3 questions to Gunther Peeters, VP Europe
– Presentation of VEXIM’s developments and key figures
– Highlights of the second half of 2016
– Press …Lire plus

VEXIM presents its financial agenda for 2017

VEXIM presents its financial agenda for 2017
 
Toulouse, December 12th, 2016 – VEXIM (FR0011072602 – ALVXM / PEA‐PME eligible), a medical device company specializing in the minimally invasive treatment of vertebral fractures, presents its preliminary financial agenda for 2017.

 
* Subject to modification. Press releases are distributed either before the financial markets opening, or after the closure.
Financial reporting schedule:
2016 sales results: January 17, 2017*
*indicative date, subject to change

VEXIM again awarded « Fastest growing listed company » in the 2016 Technology Fast 50 for Southwestern France by Deloitte In Extenso

VEXIM again awarded « Fastest growing listed company » in the 2016 Technology Fast 50 for Southwestern France by Deloitte In Extenso
 
Toulouse, November 16th 2016 – VEXIM (FR0011072602 – ALVXM / PEA‐PME eligible), a medical device company specializing in the minimally invasive treatment of vertebral fractures, announces that the company has again received the Award of the fastest growing listed company in the 2016 Technology Fast 50 for Southwestern France …Lire plus

+37% sales increase to €13.3 million as of September 30, 2016 (9 months)

+37% sales increase to €13.3 million as of September 30, 2016 (9 months)
New quarterly sales record
 

Sales growth of 32% vs. Q3 2015 reaching €4.7 million

International sales growth of +65% vs. Q3 2015

Continued strong adoption of the SpineJack® technology
 
Toulouse, October 13th 2016 – VEXIM (FR0011072602 – ALVXM / PEA‐PME), a medical device company specializing in the minimally invasive treatment of vertebral fractures, today announces its consolidated sales results for the third quarter 2016.
“Vexim …Lire plus